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Introduction:  
Postoperative ileus (POI), the impairment of gastrointestinal motility after abdominal surgery, is mainly 
due to intestinal muscular inflammation triggered by surgical handling. Hydrogen sulfide (H2S), known 
as a toxic gas, has been recognized as an important mediator of many physiological processes, 
including inflammation and H2S is now exploited therapeutically for its anti-inflammatory effects. The 
slow-release H2S donor GYY4137 was shown to reduce gastrointestinal inflammation, but was not 
tested yet in POI. ATB-346 is a H2S-releasing derivative of the non-steroidal anti-inflammatory drug 
(NSAID) naproxen, developed to reduce gastrointestinal injury of naproxen when applied for rheumatic 
conditions.  NSAIDs are commonly used to treat pain and inflammation in POI, because of their opioid-
sparing effects.  
 
Aim: 
The aim of this study was to investigate the effect of GYY4137, ATB-346 and naproxen on intestinal 
inflammation and gastrointestinal transit in POI. 
Methods: 
C57Bl6J mice were fasted for 7 h, anesthetized (isoflurane) and after laparotomy, POI was induced by 
compressing the small intestine with cotton applicators (intestinal manipulation; IM) for 5 min. 
GYY4137 (50 mg/kg, intraperitoneally), ATB-346 (16 mg/kg, intragastrically) or an equimolar dose of 
naproxen (10 mg/kg, intragastrically) were administered 1 h before IM. Gastrointestinal transit was 
assessed 24 h postoperatively using fluorescent imaging 90 min after fluorescein gavaging (geometric 
centre [GC] of gastrointestinal fluorescein progression). The small intestine was divided in 6 equal 
parts; mucosa-free muscularis segments were prepared and stored at -80° C for later analysis of 
myeloperoxidase (MPO) activity as an index of leukocyte infiltration, of the inflammatory cytokines 
interleukin (IL-)6, IL-1β and monocyte chemotactic protein 1 (MCP-1), and of  COX-2 and inducible NO 
synthase (iNOS) activity.  
Results: 
IM profoundly delayed transit (GC: 3.6 ± 0.5 versus 9.0 ± 0.4 in non-operated controls; mean ± s.e.m. 
of n = 8 per group). Pre-treatment with GYY4137 (GC: 7.6 ± 0.5) and ATB-346 (GC: 8.4 ± 0.3) prevented 
the delayed transit seen after IM while naproxen only partially did (GC: 5.9 ± 0.5). Administration of 
GYY4137 and ATB-346 significantly reduced the increase in MPO activity and in IL-6, IL-1β and MCP-1 
levels in the intestinal muscularis caused by IM; the reduction by naproxen was less pronounced and 
only reached significance for MPO activity and IL-6 levels. All treatments significantly reduced the 
increase in COX-2 activity caused by IM, naproxen not being less effective than GYY4147 and ATB-346 
for this parameter. Preliminary data on part of the tissues of each group suggest that GYY4137 and 
ATB-346 but not naproxen are able to reduce the IM-induced elevation of iNOS activity. 
Conclusion: 
The study shows that naproxen partially prevents POI, probably through its inhibitory effect on COX-2 
activity in view of the previously established role of COX-2 in murine POI (Schwarz et al., 
Gastroenterology, 2001). However, both ATB-346 and GYY4137 were more effective, the result with 
GYY4137 showing that H2S per se can prevent POI. The mechanism of action of the H2S donors in POI 
will now be studied further. 
